Alnylam suspends dosing in bleeding disorder study after patient death

(Reuters) - Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies after one patient died.